For Canadian teams developing artificial intelligence for health, 2025 brings both urgency and opportunity. Software as a Medical Device, or SaMD, now sits at the heart of how digital tools move from prototypes to regulated clinical products. The first decisive step is defining an intended use that accurately reflects the software’s medical purpose. That statement shapes classification, evidence requirements, and, ultimately, the path to regulatory authorization. Framing it t
